Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume 106, Issue -, Pages 102378
Publisher
Elsevier BV
Online
2022-03-12
DOI
10.1016/j.ctrv.2022.102378
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
- (2022) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors
- (2021) Takeshi Johkoh et al. CHEST
- Radiation-induced lung injury: current evidence
- (2021) Marisol Arroyo-Hernández et al. BMC Pulmonary Medicine
- Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
- (2021) Sara Cherri et al. Cancers
- 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
- (2021) C.A. Powell et al. ANNALS OF ONCOLOGY
- Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
- (2021) Ophelia Yin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
- (2021) Alice Indini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
- (2021) A. Spira et al. Journal of Thoracic Oncology
- OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
- (2021) K. Nakagawa et al. Journal of Thoracic Oncology
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
- (2021) E. van Cutsem et al. ANNALS OF ONCOLOGY
- LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
- (2021) J. Cortés et al. ANNALS OF ONCOLOGY
- 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
- (2021) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
- (2021) Bob T. Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
- (2020) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study
- (2020) Yuzo Suzuki et al. Journal of Thoracic Oncology
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- (2020) Junji Tsurutani et al. Cancer Discovery
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting
- (2020) Eiko Iwasa et al. DRUG SAFETY
- Deep learning in interstitial lung disease—how long until daily practice
- (2020) Ana Adriana Trusculescu et al. EUROPEAN RADIOLOGY
- Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
- (2020) Naoto Okada et al. Scientific Reports
- Interstitial pneumonitis related to trastuzumab deruxtecan, a HER2‐targeting antibody drug conjugate, in monkeys
- (2020) Kazuyoshi Kumagai et al. CANCER SCIENCE
- Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
- (2020) Ophelia Yin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
- (2019) Natsumi Namba et al. ANNALS OF THE RHEUMATIC DISEASES
- Computer-Aided Diagnosis of Pulmonary Fibrosis Using Deep Learning and CT Images
- (2019) Andreas Christe et al. INVESTIGATIVE RADIOLOGY
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
- (2019) Jarushka Naidoo et al. Journal of the National Comprehensive Cancer Network
- The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis
- (2019) Chong Hyun Suh et al. LUNG CANCER
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank
- (2019) Ekaterina Krauss et al. Journal of Clinical Medicine
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
- (2018) Chong Hyun Suh et al. LUNG CANCER
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms
- (2018) YUICHI OZAWA et al. ANTICANCER RESEARCH
- Drug-Induced Interstitial Lung Disease: A Systematic Review
- (2018) Sarah Skeoch et al. Journal of Clinical Medicine
- Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease
- (2017) Michele R. Schaeffer et al. EUROPEAN RESPIRATORY JOURNAL
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
- (2017) Terufumi Kato et al. LUNG CANCER
- Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD
- (2017) Jean P. Du Plessis et al. RESPIROLOGY
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease
- (2015) Yasunori Enomoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
- (2014) Akihiko Gemma et al. CANCER SCIENCE
- Increased Expression of Cathepsin L: A Novel Independent Prognostic Marker of Worse Outcome in Hepatocellular Carcinoma Patients
- (2014) Jian Ruan et al. PLoS One
- Cathepsin B: Multiple roles in cancer
- (2014) Neha Aggarwal et al. Proteomics Clinical Applications
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
- (2013) William D. Travis et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
- (2012) Osamu Matsuno RESPIRATORY RESEARCH
- Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports
- (2011) Noritoshi Yoshii et al. ANTI-CANCER DRUGS
- An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
- (2010) Andrew H. Limper et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Non-invasive diagnosis of early pulmonary disease in PECAM-deficient mice using infrared pulse oximetry
- (2009) Merideth A. Early et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search